{"id":"W3154559428","doi":"10.1016/j.jid.2021.02.508","title":"484 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial","year":2021,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Placebo; Medicine; Dupilumab; Eczema Area and Severity Index; Clinical endpoint; Clinical trial; Quality of life (healthcare); Atopic dermatitis; Dermatology Life Quality Index; Internal medicine; Dosing; Regimen; Dermatology; Disease; Alternative medicine; Pathology; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006463318,0.0007312152,0.001578188,0.0001677593,0.0002614412,0.0008263107,0.0004161349,0.0007784987,0.004677243],"category_scores_gemma":[0.0006084672,0.0002336577,0.001510697,0.0002226797,0.0004775262,0.0004005557,0.0001730558,0.001812858,0.0009004033],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006694398,"about_ca_system_score_gemma":0.0004353319,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001010275,"about_ca_topic_score_gemma":0.002831835,"domain_scores_codex":[0.9996483,0.0001254019,0.00001723148,0.00005642397,0.00005376383,0.000098813],"domain_scores_gemma":[0.9997048,0.00009825316,0.00005419802,0.00001617573,0.00002083816,0.0001057091],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5045677,0.01171214,0.01399464,0.002903035,0.003840209,0.0006636639,0.000222345,0.001723667,0.0278414,0.0005578828,0.01745655,0.4145167],"study_design_scores_gemma":[0.7102422,0.1895314,0.07751498,0.0003049234,0.002487278,0.001280225,0.0001263063,0.002240754,0.006869474,0.0004155164,0.008895472,0.00009138363],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9812766,0.01169203,0.0002334045,0.0007354192,0.0001797247,0.000276675,0.001527802,0.0001628654,0.003915481],"genre_scores_gemma":[0.9916059,0.003411261,0.0005817084,0.00101989,0.0001612159,0.0002603159,0.001131421,0.00002362388,0.001804667],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004677243,"threshold_uncertainty_score":0.01564693,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05683239087304508,"score_gpt":0.3552178787715227,"score_spread":0.2983854878984776,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}